Overview
- Reporting published Tuesday says Eli Lilly and the FDA allowed a single 79-year-old to receive retatrutide through the agency’s compassionate‑use (expanded access) pathway.
- STAT’s reporting says a senior NIH clinician filed the April request citing refractory obesity with obstructive sleep apnea and pulmonary hypertension and that the application drew attention from senior health officials.
- The patient’s identity has not been disclosed and the White House publicly denied that President Trump was the recipient.
- Eli Lilly, HHS and the FDA declined to comment on individual case details while the company said it only provides investigational medicines in rare, regulated situations when patients lack other options.
- Bioethicists and clinicians called the use of compassionate use for an obesity indication unusual, and the episode has renewed debate over transparency, fairness of access, and how regulators should handle high‑demand investigational weight‑loss drugs.